Tagrisso (osimertinib) , First Adjuvant Therapy for Most Common Type of Lung Cancer
19 Dicembre 2020
The U.S. Food and Drug Administration has approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have
